Stryker (NYSE:SYK) received a $170.00 target price from analysts at Oppenheimer in a note issued to investors on Friday. The brokerage presently has a “hold” rating on the medical technology company’s stock. Oppenheimer’s price objective would suggest a potential downside of 0.73% from the company’s previous close.

A number of other brokerages have also issued reports on SYK. Zacks Investment Research lowered Stryker from a “buy” rating to a “sell” rating in a research note on Wednesday, July 18th. BMO Capital Markets reissued a “hold” rating and set a $174.00 price target on shares of Stryker in a research note on Thursday, July 12th. JPMorgan Chase & Co. raised their price target on Stryker to $200.00 and gave the stock an “overweight” rating in a research note on Thursday, September 13th. Citigroup raised their price target on Stryker from $171.00 to $173.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 25th. Finally, Cantor Fitzgerald raised their price target on Stryker from $170.00 to $175.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 25th. Seven investment analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $181.81.

NYSE:SYK opened at $171.25 on Friday. The company has a market capitalization of $64.09 billion, a PE ratio of 24.16, a P/E/G ratio of 2.36 and a beta of 0.64. Stryker has a 1 year low of $146.80 and a 1 year high of $179.84. The company has a debt-to-equity ratio of 0.60, a current ratio of 1.91 and a quick ratio of 1.21.

Stryker (NYSE:SYK) last posted its quarterly earnings data on Thursday, October 25th. The medical technology company reported $1.69 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.68 by $0.01. The business had revenue of $3.24 billion during the quarter, compared to analyst estimates of $3.26 billion. Stryker had a return on equity of 28.00% and a net margin of 9.31%. Research analysts expect that Stryker will post 7.28 EPS for the current fiscal year.

In other Stryker news, VP M Kathryn Fink sold 415 shares of the firm’s stock in a transaction on Monday, November 5th. The stock was sold at an average price of $166.56, for a total transaction of $69,122.40. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, VP Katherine Ann Owen sold 37,866 shares of the firm’s stock in a transaction on Wednesday, September 5th. The stock was sold at an average price of $166.84, for a total value of $6,317,563.44. Following the transaction, the vice president now owns 11,367 shares in the company, valued at $1,896,470.28. The disclosure for this sale can be found here. Insiders have sold a total of 39,031 shares of company stock worth $6,520,313 over the last 90 days. 7.40% of the stock is currently owned by company insiders.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in SYK. Canada Pension Plan Investment Board increased its holdings in shares of Stryker by 2,573.1% in the 3rd quarter. Canada Pension Plan Investment Board now owns 202,302 shares of the medical technology company’s stock valued at $35,945,000 after acquiring an additional 194,734 shares during the period. Winslow Capital Management LLC increased its holdings in shares of Stryker by 215,255.1% in the 3rd quarter. Winslow Capital Management LLC now owns 1,109,079 shares of the medical technology company’s stock valued at $197,061,000 after acquiring an additional 1,108,564 shares during the period. DekaBank Deutsche Girozentrale increased its holdings in shares of Stryker by 12.4% in the 3rd quarter. DekaBank Deutsche Girozentrale now owns 226,427 shares of the medical technology company’s stock valued at $38,488,000 after acquiring an additional 25,015 shares during the period. FMR LLC increased its holdings in shares of Stryker by 4.8% in the 3rd quarter. FMR LLC now owns 5,581,594 shares of the medical technology company’s stock valued at $991,737,000 after acquiring an additional 253,732 shares during the period. Finally, Blue Fin Capital Inc. increased its holdings in shares of Stryker by 13.8% in the 3rd quarter. Blue Fin Capital Inc. now owns 7,047 shares of the medical technology company’s stock valued at $1,252,000 after acquiring an additional 857 shares during the period. Institutional investors own 74.71% of the company’s stock.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical devices for use in various medical specialties.

Further Reading: Short Selling Stocks, A Beginner’s Guide

Analyst Recommendations for Stryker (NYSE:SYK)

Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.